{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:03:46Z","timestamp":1793070226809,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010259","name":"American Psychiatric Association Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jsat.2022.108918","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T02:09:58Z","timestamp":1666750198000},"page":"108918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["A qualitative analysis of barriers to opioid agonist treatment for racial\/ethnic minoritized populations"],"prefix":"10.1016","volume":"144","author":[{"given":"Jawad M.","family":"Husain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Cromartie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Fitzelle-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Brochier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina P.C.","family":"Borba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Montalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jsat.2022.108918_bb0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience","volume":"171","author":"Alford","year":"2011","journal-title":"Arch. Int. Med."},{"key":"10.1016\/j.jsat.2022.108918_bb1000","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"1","key":"10.1016\/j.jsat.2022.108918_bb0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1077558713503188","article-title":"Adoption of evidence-based clinical innovations: The case of buprenorphine use by opioid treatment programs","volume":"71","author":"Andrews","year":"2014","journal-title":"Med. Care Res. Rev.MCRR"},{"issue":"6","key":"10.1016\/j.jsat.2022.108918_bb0015","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11606-008-0561-9","article-title":"Differences in the patterns of health care system distrust between blacks and whites","volume":"23","author":"Armstrong","year":"2008","journal-title":"J. General Int. Medi."},{"issue":"8","key":"10.1016\/j.jsat.2022.108918_bb0020","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2020.8969","article-title":"Therapies offered at residential addiction treatment programs in the United States","volume":"324","author":"Beetham","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2022.108918_bb0025","author":"Boston Medical Center"},{"issue":"2","key":"10.1016\/j.jsat.2022.108918_bb0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual.Res.Psychol."},{"issue":"2","key":"10.1016\/j.jsat.2022.108918_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1353\/cpr.2013.0025","article-title":"Translating community-based participatory research (CBPR) principles into practice: Building a research agenda to reduce intimate partner violence","volume":"7","author":"Burke","year":"2013","journal-title":"Progress in Community Health Partnerships : Research, Education, and Action"},{"key":"10.1016\/j.jsat.2022.108918_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108146","article-title":"A systematic review of patients\u2019 and providers\u2019 perspectives of medications for treatment of opioid use disorder","volume":"119","author":"Cioe","year":"2020","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.jsat.2022.108918_bb0045","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2307\/1229039","article-title":"Mapping the margins: Intersectionality, identity politics, and violence against women of color","volume":"43","author":"Crenshaw","year":"1990","journal-title":"Stanford Law Rev."},{"issue":"3","key":"10.1016\/j.jsat.2022.108918_bb0050","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jama.2016.9795","article-title":"Clinical Management of Opioid use Disorder","volume":"316","author":"Dunlap","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2022.108918_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106845","article-title":"Growing racial\/ethnic disparities in overdose mortality before and during the COVID-19 pandemic in California","volume":"153","author":"Friedman","year":"2021","journal-title":"Prev. Med."},{"issue":"8","key":"10.1016\/j.jsat.2022.108918_bb0060","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001\u20132014","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatrics"},{"issue":"12","key":"10.1016\/j.jsat.2022.108918_bb0065","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2105\/AJPH.2016.303483","article-title":"Is the prescription opioid epidemic a white Problem?","volume":"106","author":"Hansen","year":"2016","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.jsat.2022.108918_bb0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City","volume":"164","author":"Hansen","year":"2016","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.jsat.2022.108918_bb0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/10826084.2017.1385633","article-title":"At the expense of a life: Race, class, and the meaning of buprenorphine in pharmaceuticalized \u201cCare\u201d","volume":"53","author":"Hatcher","year":"2018","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2022.108918_bb0080","series-title":"Drug Overdose Deaths in the United States, 1999\u20132017. 329","first-page":"8","author":"Hedegaard","year":"2018"},{"key":"10.1016\/j.jsat.2022.108918_bb0085","article-title":"Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use","volume":"227","author":"Hollander","year":"2021","journal-title":"DrugAlcohol Depend."},{"key":"10.1016\/j.jsat.2022.108918_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108213","article-title":"Impact of 12 step mutual help groups on drug use disorder patients across six clinical trials","volume":"215","author":"Humphreys","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.jsat.2022.108918_bb0095","first-page":"428","article-title":"Addiction, race, and the structurally vulnerable: Addiction, race, and the structurally vulnerable","volume":"29","author":"Jegede","year":"2020","journal-title":"m. J. Addict."},{"issue":"8","key":"10.1016\/j.jsat.2022.108918_bb0100","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2105\/AJPH.90.8.1212","article-title":"Levels of racism: A theoretic framework and a gardener\u2019s tale","volume":"90","author":"Jones","year":"2000","journal-title":"Am. J. Public Health"},{"issue":"5","key":"10.1016\/j.jsat.2022.108918_bb0105","doi-asserted-by":"crossref","first-page":"e205852","DOI":"10.1001\/jamanetworkopen.2020.5852","article-title":"Incidence of treatment for opioid use disorder following nonfatal overdose in commercially insured patients","volume":"3","author":"Kilaru","year":"2020","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.jsat.2022.108918_bb0110","first-page":"736","article-title":"The narcotics bureau and the Harrison act: Jailing the healers and the sick","volume":"62","author":"King","year":"1953","journal-title":"ale Law J."},{"issue":"4","key":"10.1016\/j.jsat.2022.108918_bb0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v25n04_09","article-title":"Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence","volume":"25","author":"Kissin","year":"2006","journal-title":"J.Addict. Dis."},{"issue":"2","key":"10.1016\/j.jsat.2022.108918_bb0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ADM.0b013e3181b41a32","article-title":"Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations","volume":"4","author":"Knudsen","year":"2010","journal-title":"J. Addict. Med."},{"issue":"9","key":"10.1016\/j.jsat.2022.108918_bb0125","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by Race\/Ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.jsat.2022.108918_bb0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/dar.12442","article-title":"A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South WalesAustralia","volume":"36","author":"Larney","year":"2017","journal-title":"Drug and Alcohol Rev."},{"issue":"7","key":"10.1016\/j.jsat.2022.108918_bb0135","first-page":"667","article-title":"Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge","volume":"26","author":"Lee","year":"2017","journal-title":"m. J. Addict."},{"issue":"2","key":"10.1016\/j.jsat.2022.108918_bb0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1300\/J069v26n02_03","article-title":"Outcomes of buprenorphine maintenance in office-based practice","volume":"26","author":"Magura","year":"2007","journal-title":"J. Addict. Dis."},{"issue":"6","key":"10.1016\/j.jsat.2022.108918_bb0145","first-page":"572","article-title":"Three-year retention in buprenorphine treatment for opioid use disorder nationally in the veterans health administration","volume":"26","author":"Manhapra","year":"2017","journal-title":"m. J. Addict."},{"key":"10.1016\/j.jsat.2022.108918_bb0150","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"103","key":"10.1016\/j.jsat.2022.108918_bb0155","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.socscimed.2013.06.032","article-title":"Structural competency: Theorizing a new medical engagement with stigma and inequality","volume":"1982","author":"Metzl","year":"2014","journal-title":"Soc. Sci. Med."},{"issue":"5","key":"10.1016\/j.jsat.2022.108918_bb0160","first-page":"339","article-title":"Long-term retention in an outpatient behavioral health clinic with buprenorphine","volume":"28","author":"Montalvo","year":"2019","journal-title":"m. J. Addict."},{"key":"10.1016\/j.jsat.2022.108918_bb0165","series-title":"Narcotics anonymous and persons receiving medication-assisted treatment (Pamphlet)","author":"NA World Services, Inc.","year":"2016"},{"issue":"9","key":"10.1016\/j.jsat.2022.108918_bb0170","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research: A synthesis of recommendations","volume":"89","author":"O\u2019Brien","year":"2014","journal-title":"Acad. Med."},{"key":"10.1016\/j.jsat.2022.108918_bb0175","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","article-title":"Stigma at every turn: Health services experiences among people who inject drugs","volume":"57","author":"Paquette","year":"2018","journal-title":"Inter. J. Drug Policy"},{"issue":"2","key":"10.1016\/j.jsat.2022.108918_bb0180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/archpediatrics.2008.521","article-title":"Racial differences in parents\u2019 distrust of medicine and research","volume":"163","author":"Rajakumar","year":"2009","journal-title":"Arc. Pediatr. Adoles. Med."},{"key":"10.1016\/j.jsat.2022.108918_bb0185","series-title":"Racism triggers me to drink, but zoom-bombers won\u2019t let me be black in AA meetings","author":"Richard-Craven","year":"2021"},{"issue":"3","key":"10.1016\/j.jsat.2022.108918_bb0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jsat.2006.06.017","article-title":"Patterns of organization and management in private and public substance abuse treatment programs","volume":"31","author":"Roman","year":"2006","journal-title":"J. Sub. Abuse Treat."},{"issue":"1","key":"10.1016\/j.jsat.2022.108918_bb0195","doi-asserted-by":"crossref","first-page":"134","DOI":"10.15288\/jsa.2000.61.134","article-title":"Alcoholics anonymous and the use of medications to prevent relapse: An anonymous survey of member attitudes","volume":"61","author":"Rychtarik","year":"2000","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.jsat.2022.108918_bb0200","series-title":"Drug Enforcement in the United States: History, Policy, and Trends","first-page":"30","author":"Sacco","year":"2014"},{"issue":"5","key":"10.1016\/j.jsat.2022.108918_bb0205","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/ADM.0b013e318297021e","article-title":"Meaning and methadone: Patient perceptions of methadone dose and a model to promote adherence to maintenance treatment","volume":"7","author":"Sanders","year":"2013","journal-title":"J. Addict. Med."},{"issue":"4","key":"10.1016\/j.jsat.2022.108918_bb0210","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","article-title":"Saturation in qualitative research: Exploring its conceptualization and operationalization","volume":"52","author":"Saunders","year":"2018","journal-title":"Quality & Quantity"},{"key":"10.1016\/j.jsat.2022.108918_bb0215","article-title":"Drug and opioid-involved overdose Deaths\u2014United States, 2013\u20132017","volume":"67","author":"Scholl","year":"2019","journal-title":"MMWR. Morb. Mortal. Weekly Rep."},{"issue":"6","key":"10.1016\/j.jsat.2022.108918_bb0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Current Psychiatry Reports"},{"issue":"3","key":"10.1016\/j.jsat.2022.108918_bb0225","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/15504263.2017.1325033","article-title":"Trends in opioid use disorder diagnoses and medication treatment among veterans with posttraumatic stress disorder","volume":"13","author":"Shiner","year":"2017","journal-title":"J.Dual Diagn."},{"key":"10.1016\/j.jsat.2022.108918_bb0230","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jsat.2022.108918_bb0235","first-page":"19","article-title":"Drug overdose deaths involving fentanyl, 2011\u20132016","volume":"68","author":"Spencer","year":"2019","journal-title":"Natl.Vital Stat. Rep."},{"key":"10.1016\/j.jsat.2022.108918_bb0240","article-title":"The SAMHSA evaluation of the impact of the DATA waiver program","author":"Stanton","year":"2006","journal-title":"Substance Abuse and Mental Health Services Administration."},{"issue":"4","key":"10.1016\/j.jsat.2022.108918_bb0245","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08897077.2018.1449166","article-title":"A population-based examination of trends and disparities in medication treatment for opioid use disorders among medicaid enrollees","volume":"39","author":"Stein","year":"2018","journal-title":"Substance Abuse"},{"issue":"8","key":"10.1016\/j.jsat.2022.108918_bb0250","first-page":"879","article-title":"Beyond misdiagnosis, misunderstanding and mistrust: Relevance of the historical perspective in the medical and mental health treatment of people of color","volume":"99","author":"Suite","year":"2007","journal-title":"J. Nat. Med. Associat."},{"issue":"2","key":"10.1016\/j.jsat.2022.108918_bb0255","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jsat.2022.108918_bb0260","series-title":"August)","author":"Waters","year":"2013"},{"key":"10.1016\/j.jsat.2022.108918_bb0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"J. Sub. Abuse Treat."},{"key":"10.1016\/j.jsat.2022.108918_bb0270","series-title":"The color and character of AA | emeritus senior research consultant chestnut health systems |","author":"White","year":"2018"},{"key":"10.1016\/j.jsat.2022.108918_bb0275","article-title":"\u201cDon\u2019t judge a book by its Cover\u201d: A qualitative study of methadone patients\u2019 experiences of stigma","volume":"11","author":"Woo","year":"2017","journal-title":"Substance Abuse: Res. Treat."}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222002008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222002008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:58:39Z","timestamp":1760039919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547222002008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":56,"alternative-id":["S0740547222002008"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108918","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A qualitative analysis of barriers to opioid agonist treatment for racial\/ethnic minoritized populations","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108918"}}